Skip to main content
AMPH
NASDAQ Life Sciences

Q3 Revenue Climbs 8% to $207.6M as BAQSIMI and Primatene Hit Records

Tom Rudovsky · Reported by PR Newswire
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$27.66
Mkt Cap
$1.177B
52W Low
$16.645
52W High
$29.52
52W Position info
66% above low
Off High info
6.3% below high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

AMPH sits 66% above its 52-week low of $16.645.

Summary

Amphastar posted Q3 net revenue of $207.6 million, up 8% from $191.8 million a year ago, with record BAQSIMI ($58.8 million, +10%) and Primatene MIST ($31.5 million, +9%) sales plus $6.6 million from newly launched ipratropium bromide. GAAP net income more than doubled to $37.8 million, or $0.87 per diluted share, though the prior-year quarter carried a $23.1 million litigation provision that flattered the comparison; adjusted non-GAAP EPS rose to $1.14 from $0.93. Gross margin compressed to 48.0% from 51.4% on lower BAQSIMI and glucagon pricing and higher IMS remediation and plant expansion costs, and glucagon revenue fell 37% on competition while epinephrine slipped 19% on slower releases tied to the FDA warning letter at IMS. The board added $50 million to the buyback on November 4, aimed at offsetting equity-compensation dilution. The quarter shows the top line holding up on new launches, but margin pressure and the IMS remediation remain the swing factors.

At the time of this announcement, AMPH was trading at $27.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $16.65 to $29.52. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.


Price Chart

Share this article

Copied!

AMPH - Latest Insights

AMPH
Nov 05, 2026, 4:40 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $30.10
Real-time Price: $27.80 info
Change: -$2.30 (-8%) info
Market Cap: $1.177B info
AMPH
Nov 05, 2026, 4:26 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $30.10
Real-time Price: $27.80 info
Change: -$2.30 (-8%) info
Market Cap: $1.177B info
AMPH
Aug 06, 2026, 4:50 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $20.35
Real-time Price: $27.80 info
Change: +$7.45 (+37%) info
Market Cap: $1.177B info
AMPH
Aug 06, 2026, 4:05 PM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $20.35
Real-time Price: $27.80 info
Change: +$7.45 (+37%) info
Market Cap: $1.177B info
AMPH
Jul 13, 2026, 7:20 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $18.72
Real-time Price: $27.80 info
Change: +$9.08 (+49%) info
Market Cap: $1.177B info